Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Hormone Molecular Biology and Clinical Investigation

Editor-in-Chief: Chetrite, Gérard S.

Editorial Board: Alexis, Michael N. / Baniahmad, Aria / Beato, Miguel / Bouillon, Roger / Brodie, Angela / Carruba, Giuseppe / Chen, Shiuan / Cidlowski, John A. / Clarke, Robert / Coelingh Bennink, Herjan J.T. / Darbre, Philippa D. / Drouin, Jacques / Dufau, Maria L. / Edwards, Dean P. / Falany, Charles N. / Fernandez-Perez, Leandro / Ferroud, Clotilde / Feve, Bruno / Flores-Morales, Amilcar / Foster, Michelle T. / Garcia-Segura, Luis M. / Gastaldelli, Amalia / Gee, Julia M.W. / Genazzani, Andrea R. / Greene, Geoffrey L. / Groner, Bernd / Hampl, Richard / Hilakivi-Clarke, Leena / Hubalek, Michael / Iwase, Hirotaka / Jordan, V. Craig / Klocker, Helmut / Kloet, Ronald / Labrie, Fernand / Mendelson, Carole R. / Mück, Alfred O. / Nicola, Alejandro F. / O'Malley, Bert W. / Raynaud, Jean-Pierre / Ruan, Xiangyan / Russo, Jose / Saad, Farid / Sanchez, Edwin R. / Schally, Andrew V. / Schillaci, Roxana / Schindler, Adolf E. / Söderqvist, Gunnar / Speirs, Valerie / Stanczyk, Frank Z. / Starka, Luboslav / Sutter, Thomas R. / Tresguerres, Jesús A. / Wahli, Walter / Wildt, Ludwig / Yang, Kaiping / Yu, Qi

CiteScore 2018: 2.43

SCImago Journal Rank (SJR) 2018: 0.947
Source Normalized Impact per Paper (SNIP) 2018: 0.837

See all formats and pricing
More options …
Volume 40, Issue 1


A new prospective on the role of melatonin in diabetes and its complications

Jia Xin Mok
  • School of Medical Laboratory Science, University of Otago, Dunedin 9054, New Zealand
  • University of Otago, Dunedin School of Medicine, Department of Pathology, Medical Laboratory Science, Dunedin 9016, New Zealand
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Jack Hau Ooi / Khuen Yen Ng / Rhun Yian Koh / Soi Moi Chye
  • Corresponding author
  • International Medical University, School of Health Science, Kuala Lumpur 57000, Malaysia
  • School of Health Science, Division of Biomedical Science and Biotechnology, International Medical University, No. 126, Jalan Jalil Perkasa 19, Bukit Jalil, 57000 Kuala Lumpur, Malaysia, Phone: +60-3-27317220, Fax: +06-3-86567229
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2019-11-06 | DOI: https://doi.org/10.1515/hmbci-2019-0036


Melatonin is a hormone secreted by the pineal gland under the control of the circadian rhythm, and is released in the dark and suppressed during the day. In the past decades, melatonin has been considered to be used in the treatment for diabetes mellitus (DM). This is due to a functional inter-relationship between melatonin and insulin. Elevated oxidative stress is a feature found in DM associated with diabetic neuropathy (DN), retinopathy (DR), nephropathy and cardiovascular disease. Reactive oxygen species (ROS) and nitrogen oxidative species (NOS) are usually produced in massive amounts via glucose and lipid peroxidation, and this leads to diabetic complications. At the molecular level, ROS causes damage to the biomolecules and triggers apoptosis. Melatonin, as an antioxidant and a free radical scavenger, ameliorates oxidative stress caused by ROS and NOS. Besides that, melatonin administration is proven to bring other anti-DM effects such as reducing cellular apoptosis and promoting the production of antioxidants.

Keywords: antioxidant; diabetes; melatonin; neuropathy; retinopathy


Diabetes mellitus (DM) is a global health concern as 387 million people worldwide are afflicted with this disorder [1]. According to World Health Organization (WHO), it is estimated that around 3.4 million people have died from the consequences of hyperglycemia. Moreover, the number of deaths is predicted to double between 2000 and 2030 [2]. The two major types of DM are type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). T1DM is insulin-dependent diabetes which is caused by an autoimmune disease whereas T2DM is insulin-independent diabetes that is characterized by abnormally high insulin resistance. A combination of risk factors such as age, obesity, sedentary lifestyle or environment factors is thought to trigger T2DM in individuals that are genetically susceptible [3], [4]. Patients suffering from T2DM are often observed to be accompanied by other complications such as diabetic neuropathy (DN), retinopathy, nephropathy and cardiovascular disease [4].

Hyperglycemia produces ROS through a few mechanisms such as mitochondrial dysfunction, labile glycation, glucose auto-oxidation and the intracellular polyol pathway [5]. An increased level of glucose induces the production of advanced glycation end-products (AGEs) which leads to ROS production and the activation of inflammation signaling cascades, ultimately causing diabetic complications [6]. In DM, AGEs production is observed to be enhanced in diabetic patients compared to healthy controls [7]. Thus, the imbalance between levels of intracellular ROS and antioxidants is likely the cause of diabetic complications [8].

Melatonin, a hormone which is produced by pineal gland, has known anti-oxidant properties. Studies have shown that melatonin may be associated with DM in many different ways. Emerging evidence shows that melatonin reduces diabetic complications by ameliorating oxidative damage [9]. Pancreatic beta (β) cells are especially susceptible to oxidative stress as they are known to produce high endogenous levels of ROS and do not express much of the anti-oxidative enzymes. Apart from serving as a ROS scavenger, melatonin may reduce diabetic complications such as DN, cardiovascular diseases and DR in many different ways [10]. These roles of melatonin will also be discussed in this review.

The relationship of melatonin and diabetes

Melatonin signaling and insulin secretion

Melatonin secretion is maintained by the biological circadian rhythm where its production is released in the dark at night and inhibited when exposed to daylight. Synthesis of melatonin involves several steps where the amino acid, tryptophan is converted into serotonin which then undergoes acetylation by the enzyme serotonin-N-acetyltransferase (SNAT), finally being converted into melatonin by hydroxyindole-O-methyltransferase (HIOMT) [11]. Melatonin receptors are G-protein coupled receptors (GPCR). The two main types of melatonin receptors in humans are melatonin receptor 1 (MT1) and melatonin receptor 2 (MT2) [12], [13]. Transcription levels of melatonin receptors are seemingly inversely proportional to the concentration of plasma melatonin, thus, reflecting that the regulation is probably modulated by a negative feedback mechanism [14], [15].

Insulin secretion is mediated through MT1 and MT2 [16]. When the melatonin receptors are coupled to inhibitory G-proteins (Gi), the Gi-protein signaling cascade is activated and subsequently inhibits AC/cAMP and GC/cGMP pathways that results in cAMP reduction [16], [17]. cAMP is the potentiator of insulin secretion. Therefore, when cAMP is reduced, insulin production is decreased. This is supported by a study that shows the binding of melatonin to its receptors would result in decreased plasma insulin level [17], [18]. However, insulin secretion is induced by coupling to Gq/11, where phospholipase C is then activated via melatonin receptors and increases inositol triphosphate (IP3) or glucagon secretion which is stimulated by melatonin [19].

During day time, melatonin level is low and the secretion of insulin is elevated, whereas at night, the melatonin level is raised along with observations of decreased levels of insulin with increased glucose levels [20]. Moreover, melatonin secretion is shown to decrease with age concurrent with increased insulin resistance [21]. MT1 and MT2 receptors are expressed in the pancreatic tissues and islets in humans and rodents [22]. Hence, melatonin might directly regulate the production of insulin or glucagon by acting on the pancreatic islets. Immunoprecipitation and immunoblotting results showed melatonin regulates the growth and differentiation of pancreatic cells [23]. When pinealectomized rats were administered with melatonin, insulin production was increased in pancreatic β-cells along with a rise in the number of insulin receptors on the hepatocyte membranes [24]. This suggests that melatonin is crucial for the production of insulin in the pancreatic cells. Suppression of melatonin secretion due to exposure to nocturnal light has been thought to be a critical risk factor of T2DM [25]. In an in-vivo study, increased insulin secretion and larger β-cell mass in MT2 knockout mice can be observed compared to the wild-type litter mates. The results suggested that this could be due to the lack of inhibitory effect of melatonin as cAMP levels rose in MT2 knockout mice [26]. This study suggests that MT2 plays an important role in the inhibitory effect of melatonin on insulin secretion. These results clearly depicted functional interrelationship between melatonin and insulin can be seen [27].

MTNR1B gene variants and diabetes

The role of the MTNR1B gene (the gene that encodes the MT2 receptor), in regulating the plasma glucose level and the pathogenesis of T2DM have been previously reported [28]. Variants of the MTNR1B locus such as rs1387153 and rs10830963 have been associated with fasting glucose and T2DM. Specificity, MT2 acts primarily on the pancreas due to the close association of rs10830963 single-nucleotide polymorphisms (SNPs) with impaired insulin secretion [29].

The MTNR1B variant manifests increased glucose despite elevated insulin-to-glucagon ratio and predominates in β-cells unlike MTNR1A which is expressed in ⍺-cells. Rs10830963 carriers are observed to have defects in early-phase insulin production. Hence, this contributes to the rise of glucose plasma levels in carriers without T2DM [29], [30]. Besides that, has also been learned that rs10830963 SNPs exhibits a bigger effect on a prediabetic person and a smaller effect when the person is on the transition to the diabetic state [31]. However, it is unknown whether the increase of mRNA levels of MTNR1B would be correlated to the increase of MT2 expression levels as it is found to not be a trait of T2DM patients and not expressed increasingly in the pancreatic islets of T2DM [32]. Nevertheless, MTNR1B mRNA levels are high in the pancreatic islets of rs10830963-variant carriers than people without [33]. Variants affecting the receptor can either lead to gain or loss of function. MTNR1B has shown a loss-of-function phenotype according to the statistical analysis which established a solid link between the loss of MT2 receptor function and the risk of T2DM. Therefore, it increases the risk of T2DM 6 times [34] (Figure 1).

The relationship of MTNR1B locus variant and T2DM. The two common variants; rs1387153 SNP and rs10830963 SNP expand mRNA expression in β cells which further increases melatonin Gi-protein signaling cascade and results in reduction of cAMP, insulin level leads to hyperglycaemia and T2DM development.Figure 1 was drawn by Jia Xin Mok
Figure 1:

The relationship of MTNR1B locus variant and T2DM.

The two common variants; rs1387153 SNP and rs10830963 SNP expand mRNA expression in β cells which further increases melatonin Gi-protein signaling cascade and results in reduction of cAMP, insulin level leads to hyperglycaemia and T2DM development.

Melatonin and glucose homeostasis

Glucose homeostasis and secretion of insulin from pancreatic β-cells are maintained by the pineal gland [35]. A decreased level of systemic melatonin circulating in the body and upregulated expression of mRNA in melatonin membrane receptor are observed in T2DM patients [36]. It is assumed that this higher expression of melatonin membrane receptor mRNA is to compensate for the low melatonin in T2DM patients [37]. Moreover, polymorphisms within the MTNR1B gene carrying the risk allele G has shown to increase the mRNA expression in the β-cells which causes the reduction of insulin secretion due to the decreased production of cAMP. Consequently, this increases the level of plasma glucose leading to T2DM [38]. Clinical results have indicated that melatonin improves glycemic control and insufficiency of melatonin may lead to T2DM [39]. Besides that, melatonin exerts glycemic control via reducing fasting plasma glucose (FPG) but not through increasing insulin secretion [40]. Melatonin prevents the β-cells from being overstrained functionally in T2DM and inhibits insulin secretion from the β-cells [16]. High levels of melatonin and low plasma insulin levels can be observed in T1DM and vice versa in T2DM [41], [42]. A recent study has shown that the removal of MT1 has resulted in increased glucose intolerance and insulin resistance. The daily blood glucose level rhythm was altered or affected showing increasing glucose concentrations during night time when a pinealectomy is performed to remove endogenous melatonin levels [43]. According to a study using pinealectomized rats, glucose and glucagon levels increased while insulin levels were decreased. Glucose intolerance is markedly seen but with melatonin treatment, this condition is attenuated [44] (Figure 2).

The role of melatonin in glucose homeostasis. T1DM increases melatonin production through activation of the enzyme cascade. Impaired β islet cells in TD1M in turn decreases the production of insulin, and increases level of glucagon resulting in hyperglycemia. Depletion of melatonin in T2DM results in increase of mRNA expression of melatonin membrane receptor. Impaired insulin signaling enhances the rise in insulin level leading to β cells exhaustion, combining with high glucagon level leads to hyperglycemia.Figure 2 was drawn by Jia Xin Mok
Figure 2:

The role of melatonin in glucose homeostasis.

T1DM increases melatonin production through activation of the enzyme cascade. Impaired β islet cells in TD1M in turn decreases the production of insulin, and increases level of glucagon resulting in hyperglycemia. Depletion of melatonin in T2DM results in increase of mRNA expression of melatonin membrane receptor. Impaired insulin signaling enhances the rise in insulin level leading to β cells exhaustion, combining with high glucagon level leads to hyperglycemia.

Melatonin and oxidative stress

Melatonin is an antioxidant which scavenges ROS (such as hydrogen peroxide and peroxynitrite anion) and reactive nitrogen species (RNS) [45], [46]. It also detoxifies hydroxyl radicals and also peroxyl radicals. Moreover, it also upregulates antioxidant enzyme gene expression [47]. According to findings of the study, melatonin increased antioxidants enzyme (glutathione, catalase, superoxide dismutase) activities in turn downregulated triglycerides, total cholesterol and low-density lipoprotein (LDL) concentration in STZ-treated diabetic rats [48]. Oxidative stress plays an important role in the development of diabetic complications such as diabetic nephropathy, DR and cardiomyopathy.

Excessive production of ROS can lead to cellular damage of membranes, proteins, lipids and DNA [49]. ROS are produced in mitochondria and also non-mitochondrial sites, for instance, peroxisomes [50]. In diabetes, hyperglycemia increases levels of nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH2) and inhibits the delivery of protons to complex III in the electron transport chain. This causes excessive production of ROS and leads to a buildup of oxidative stress [51]. Influx of glucose rises intracellular glucose concentration and subsequently increases the production of superoxide anions in non-insulin dependent cells such as vascular endothelium cells [52].

Oxidative stress causes defective insulin signaling and impaired insulin secretion which then leads to insulin resistance and complications [53]. According to the experiments that were carried out, additional support is contributed to melatonin being helpful for DM treatment and metabolic syndrome as melatonin may perform an anti-atherogenic effect [54].

Melatonin in diabetes

A decreased level of melatonin secretion is independently associated with the increased risk of type 2 diabetes developing in a patient. Hence, variant melatonin membrane receptors and low secretion of melatonin aggravate the risk of developing T2DM [13]. A higher risk of diabetes was found to be associated with low melatonin level in women in a cohort study [55]. A12-year longitudinal study which included 370 women with T2DM and 370 participants of matched control proved that diminished melatonin secretion level at night is independently associated with a high risk of developing T2DM [56].

A report has recently proved that melatonin production in the pineal gland of a streptozotocin (STZ)-induced diabetic rats is damaged due to hyperglycemia. Therefore, suggesting that deficiency of melatonin could be the representation of the hallmark of diabetic patients [57]. Melatonin can induce secretion of insulin by the IP3 signaling pathway and also improve β-cell function. Consequently, beneficial effects can be observed on glucose homeostasis when melatonin supplement is introduced [58]. Thus, according to a study using young Zucker diabetic fatty (ZDF) rats, glycemic control in young ZDF rats can be observed to improve with melatonin treatment [59].

Melatonin treatment is known to lower fasting hyperglycemia, plasma leptin, insulin and serum fatty acids. On the other hand, it is known to raise adiponectin and ameliorate insulin resistance [59], [60]. Besides that, melatonin treatment used in the STZ-induced diabetes rats have demonstrated improved insulin sensitivity in their adipose tissue. However, a marked hypogonadism is shown. This could be caused by the changes in hypothalamic circuitries which are part of the reproductive control [61].

Melatonin in diabetic cardiomyopathy

Coronary heart disease (CHD) is one of the complications of DM [62]. More than 80% of deaths in T2DM patients is caused by CHD. Metabolic disorders in T2DM patients may lead to inflammation and the production of free radicals which then causes vascular disorders [63], [64]. Diabetic cardiomyopathy is a diabetes-associated condition which involves changes to the function and structure of myocardium [65]. Hyperglycemia is known to activate spleen tyrosine kinase (Syk) which suppresses the activity and expression of mitochondrial complex I (COX-I). This process inevitably increases the production of cellular and/or mitochondrial ROS and triggers cardiomyocyte death through apoptosis. Studies have also demonstrated that the apoptosis of cardiomyocytes in diabetes are partially contributed by downregulation of autophagy [66], [67], [68]. Besides that, a previous study showed that hyperglycemia induces endoplasmic reticulum (ER) stress which is a factor leading to apoptosis [69].

ROS promotes atherosclerosis through the expression of growth factors and activation of JNK stress signaling pathway. In addition, hyperglycemia leads to the accumulation of ALU-dsRNA in vascular endothelial cells and provokes ROS production. This results in a build-up of oxidative stress and endothelial cell dysfunction [70]. Antioxidant treatment has been proved to be effective at reducing oxidative stress in diabetic cardiomyopathy [71]. Melatonin is known to be one of the most potent antioxidants and also serves as a free radical scavenger which can be used as a treatment in cardiomyopathy [72], [73]. In concordance with these studies, melatonin is proved to increase antioxidants enzyme (superoxide dismutase, catalase and glutathione peroxidase) activities via phosphorylation of vascular endothelial growth factor-A (VEGF-A) and decreases the levels of mTOR expression in STZ-induced diabetic cardiomyopathy rats [74], [75].

Hyperglycemia, insulin resistance and dyslipidemia which can be characterized as a metabolic syndrome together with hypertension and central obesity might be responsible for the development of atherosclerosis in T2DM subjects. Atherosclerosis is a main risk factor for cardiovascular diseases. Few studies have shown that the progression of insulin resistance to TD2M is correlated to the development of atherosclerosis. Patients undergoing both metabolic syndrome and DM have been observed to have worse coronary lesions and obstructions as compared to patients with metabolic syndrome without diabetes [76]. High total cholesterol level is known to be a major risk factor for atherosclerosis that leads to cardiovascular diseases. Hyperlipidemia is especially prevalent in diabetic subjects [77], [78]. In a study using Zucker diabetic rats, the administration of melatonin was shown to reduce the level of LDL-cholesterol while increasing level of HDL-cholesterol in plasma, therefore suggesting melatonin is a potential protective agent to be used for the endogenous cholesterol clearance [79], [80].

Furthermore, melatonin is shown to suppress the expression level of CD95 as well as the activities of capases-8 and 5 in rat cardiac tissue. By inhibiting the caspase pathways, apoptotic events can be prevented in cardiomyocytes [81], [82]. This notion is further strengthened by other studies where melatonin was shown to be anti-apoptotic and protective against injury on cardiomyocytes [83], [84]. According to a study, melatonin membrane receptors-dependent cGMP-PKGIα signaling plays an important role in reducing oxidative stress. Therefore, Nrf-2-HO-1 and MAPK signaling which serve as the downstream targets of the cGMP-PKGIα signaling, are regulated by melatonin to reduce cardiomyocytes injury. However, the study is only limited to STZ-induced T1DM rats, and the results might not be appropriate to be extrapolated to T2DM. Melatonin also helps to inhibit hyperpermeability of the aortic endothelium and therefore improves atherosclerosis [85], [86].

Mitochondrial fission has been studied to be associated with myocardial contractile dysfunction in diabetic subjects. It was observed that melatonin prevents cardiac dysfunction in diabetes via the inhibition of mitochondrial fission and this action is mediated by dynamin-related protein (Drp-a) [87]. On the other hand, it is known that mitochondrial oxidative damage and mitochondrial dysfunction are associated with the pathogenesis of cardiac dysfunction in diabetic patients [88], [89]. Reduced clearance of dysfunctional mitochondria impairs mitophagy, ultimately leading to diabetic cardiomyopathy. Melatonin has been reported to serve as a mitophagy enhancer by eliminating the accumulation of dysfunctional mitochondria, therefore restoring the quality control of the mitochondria and improving the cardiac function [90]. The action of melatonin in modulating autophagy, reducing apoptosis and eliminating dysfunctional mitochondria were suggested to be associated with the Mst1/Sirt3 signaling pathway [91]. In conclusion, melatonin can reduce oxidative stress, apoptotic events and preserving cardiac function.

Melatonin in diabetic retinopathy (DR)

DR is a major cause of vision loss in the working-age population. It is a microvascular complication associated with diabetes [92]. During the hyperglycemic state, elevated oxidative stress can result in the thickening of the retinal basement which is presented as microangiopathy observed in DR. Besides that, as the retinal tissue is rich in lipids, it is particularly prone to oxidative stress [93], [94]. As oxidative stress is augmented in diabetes, increased vascular leakage and permeability lead to the development of diabetic macular edema (DME) [94], [95]. Oxidative stress triggers the para-inflammation process to amend the retina membrane. However, when this is not successful, it will lead to a chronic condition of low-grade inflammation [96]. Capillary occlusion occurs as a result of a high amount of leukocytes produced during low-grade inflammation in the retina. This results in the subsequent upregulation of VEGF as an ischemic condition is induced.

Oxidative stress, inflammation and autophagy are known to be part of the pathogenesis of DR [97], [98]. As discussed in the previous section, oxidative stress damages biomolecules which leads to apoptosis and this also upregulates expression levels of VEGF and matrix metallopeptidase 9 (MMP9) [99], [100]. VEGF induces vascular dilation, microaneurysm, neovascularization, disruption of the blood-retinal barrier, angiogenesis and other abnormalities related to the vessels. Thiobarbituric acid reactive substances (TBARS), a lipid peroxidation marker, and advanced oxidation protein products (AOPP), a protein oxidation marker, have been observed to rise in the retina of diabetic-induced rats and also in the serum of patients suffering from DR [100], [101], [102]. Apoptosis of the retina neurons is also imparted into the pathogenesis DR as ganglion cells are dying with increased proportional of apoptotic cells [103]. Furthermore, nitrosative stress is increased in DR where NO is augmented through iNOS upregulation, forming peroxynitrite. Through lipid peroxidation decomposition, malondialdehyde (MDA) is produced. MDA is found to double in diabetic subjects as compared to the control group in studies [104], [105], [106], [107], [108].

Similarly, studies conducted on diabetic Sprague-Dawley rats administered with melatonin showed that melatonin decreased oxidative stress through the PI3K/Akt-Nrf2 signaling pathway. This pathway is triggered to increase the production of other antioxidants such as gluthathione and decreased inflammation through the inhibition of the NF-KB activation cascade [109], [110]. By inhibiting the NF-KB cascade, pro-inflammatory cytokines are also diminished [110]. In the retina of the diabetic rats, glutathione and glutamate cysteine ligase (GCL) are observed to be downregulated. GCL serves as the rate-limiting enzyme of the production of glutathione but when melatonin is administered, GCL level increased via Akt phosphorylation which in turn elevated Nrf2 activity [110], [111]. Subsequently, this augments the GSH level in the retina and reduces polyol pathway enzymes, of which accumulation of polyols is known to be associated with damage to the cell membranes. Melatonin delays cataract formation via decreasing cytokines such as VEGF and MMPs in DR [112].

Besides the fact that melatonin is a potent antioxidant which reduces ROS and NOS activity in the retina, it also stimulates the production of other antioxidants such as glutathione. Moreover, some studies have shown that melatonin has a role in the maintenance of the catalase retinal activity in diabetic rats [113]. Thus, melatonin can delay the development of DR [114].

Melatonin in DN

DN is a common neurological complication of diabetic patients [115]. DN includes peripheral, autonomic, proximal and focal neuropathy. Peripheral neuropathy is the most common DN complication and represents the major cause of foot ulceration, gait disturbance, amputation and neuropathic pain [115], [116], [117], [118].

There are a few types of peripheral nervous system damage that are associated with diabetes. The most common type is the stocking-glove neuropathy, which is caused by the damage of the nerves of the foot [118], [119]. Some of the earliest symptoms are detected in the feet and structural defects to the axons and Schwann cells appeared to be the predominant characteristics [119]. DN is a disorder led by a myriad of events such as hyperglycemia, dyslipidemia and increased insulin resistance interacting with one another. These events promote the activation of pathways such as polyol, AGEs production, protein kinase C (PKC), polymerase (PARP), poly(ADP-ribose) and hexosamine [119], [120]. Besides that, insulin signaling is also lost. These metabolic alterations lead to mitochondrial dysfunction, altered gene expression and ion-current defects (diminished K-channel activity and augmented Na-channel activity) together with oxidative stress and inflammation leading to nerve damage and cell death [120], [121].

A study on diabetic rats demonstrated that oxidative stress can damage a number of brain regions [122]. Another study using STZ-induced diabetic rat models showed a reduction of acetylcholinesterase activity and NAD level and an increase of MDA level. Neurotransmitters such as gamma-aminobutyric acid (GABA) and glutamate levels were altered in the hippocampus [123]. However, this is reversed by melatonin treatment and NAD and MDA levels were brought back to normal levels. As oxidative stress is elevated in the hyperglycemic condition, glial reactivity is increased. Melatonin treatment reduces gliosis in some of these brain regions [124]. A study shows melatonin reduces dopaminergic fiber degeneration in the hippocampus of the rat models [125], [126]. Besides that, melatonin significantly increases Nrf2 (a potent endogenous antioxidant) and heme oxygenase-1, diminishes ethanol-induced ROS and neuroinflammation by reducing NF-κB activation [127], [128], [129].

Melatonin has also shown to be anti-apoptotic in the neurons of diabetic patients [129], [130]. Melatonin prevents apoptosis in the neuronal cells under high glucose conditions by stimulating the PTEN-induced putative kinase 1 (PINK1) expression through the MT2/Akt/NF-kB pathway [131]. Moreover, melatonin prevents oxidative stress-induced mitochondrial dysfunction and apoptosis in high glucose-treated Schwann cells via upregulation of the Bcl2, NF-κB, mTOR, Wnt signaling pathways [132]. Increased insulin resistance which is a pathological condition observed in T2DM patients is thought to cause cognitive decline and worsening neuropathy. Insulin resistance causes ER stress and can be eliminated with melatonin administration which suppresses the ASK1 pathway [133]. The reduction of electrical stimulation in the peripheral nerves in the STZ induced diabetic rats. However, after 21 days of melatonin treatment, improvement was seen in the nerve conductivity velocity [134], [135]. Similarly, Seyit et al. also proved that melatonin significantly improves nerve conduction velocity in STZ-induced DN rats through somatosensory evoked potentials [136]. Melatonin improved in nerve regeneration by promoting the proliferation of Schwann cells in an in-vivo study [137]. Therefore, this evidence suggests that melatonin plays an important role in treating DN.


DM is one of the world’s leading cause of death which is currently affecting millions of people around the globe. Hyperglycemia in diabetes causes excessive production of ROS which then leads to a build-up of oxidative stress and induction of insulin resistance. Oxidative stress is known to be related many other diabetic complications such as DN, DR, nephropathy and cardiovascular disorders. A better treatment regimen is required to target the pathogenic pathways associated with oxidative stress to improve these diabetic conditions. Melatonin confers protection against diabetes via many different mechanisms. Melatonin plays a crucial role in glycemic control by reducing FPG. Melatonin also ameliorates insulin resistance and enhances insulin sensitivity in cells. In a nutshell, melatonin treatment can be used to improve diabetic conditions in patients and reduce the incidence of diabetic complications.

Table 1:

Summary of the role of melatonin in diabetes mellitus and its complications.


  • [1]

    You W, Henneberg M. Type 1 diabetes prevalence increasing globally and regionally: the role of natural selection and life expectancy at birth. BMJ Open Diabetes Res Care. 2016;4:1–7. Google Scholar

  • [2]

    Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world – a growing challenge. N Engl J Med. 2007;356:213–5. PubMedCrossrefGoogle Scholar

  • [3]

    Prasad RB, Groop L. Genetics of type 2 diabetes-pitfalls and possibilities. Genes. 2015;6:87–123. CrossrefPubMedGoogle Scholar

  • [4]

    Wu Y, Ding Y, Tanaka Y, Zhang W. Risk factors contributing to type 2 diabetes and recent advances in the treatment and prevention. Int J Med Sci. 2014;11:1185–200. PubMedCrossrefGoogle Scholar

  • [5]

    Bondeva T, Wolf G. Reactive oxygen species in diabetic nephropathy: friend or foe ? Nephrol Dial Transplant. 2014;29:1998–2003. CrossrefPubMedGoogle Scholar

  • [6]

    Yan SF, Ramasamy R, Schmidt AM. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract. 2008;4:285–93. CrossrefGoogle Scholar

  • [7]

    Yamagishi S. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes. Exp Gerontol. 2011;46:217–24. PubMedCrossrefGoogle Scholar

  • [8]

    Rahimi R, Nikfar S, Larijani B, Abdollahi M. A review on the role of antioxidants in the management of diabetes and its complications. Biomed Pharmacother. 2005;59:365–73. CrossrefPubMedGoogle Scholar

  • [9]

    Mayo JC, Tan D, Sainz RM, Alatorre-jimenez M. Melatonin as an antioxidant: under promises but over delivers. J Pineal Res. 2016;61:253–78. CrossrefPubMedGoogle Scholar

  • [10]

    Wang J, Wang H. Oxidative stress in pancreatic beta cell regeneration. Oxid Med Cell Longev. 2017;2017:1930261. PubMedGoogle Scholar

  • [11]

    Chattoraj A, Liu T. Melatonin formation in mammals: in vivo perspectives. Rev Endocr Metab Disord. 2009;10:237–43. CrossrefPubMedGoogle Scholar

  • [12]

    Devavry S, Legros C, Brasseur C, Cohen W, Guenin SP, Delagrange P, et al. Molecular pharmacology of the mouse melatonin receptors MT1and MT2. Eur J Pharmacol. 2012;677:15–21. CrossrefGoogle Scholar

  • [13]

    McMullan CJ, Schernhammer ES, Rimm EB, Hu FB, Forman JP. Melatonin secretion and the incidence of type 2 diabetes. J Am Med Assoc. 2013;309:1388–96. CrossrefGoogle Scholar

  • [14]

    Vanecek J. Cellular mechanisms of melatonin action. Physiol Rev. 1998;78:687–721. CrossrefPubMedGoogle Scholar

  • [15]

    Tan HY, Ng KY, Koh RY, Chye SM. Pharmacological effects of melatonin as neuroprotectant in rodent model: a review on the current biological evidence. Cell Mol Neurobiol. 2019. Google Scholar

  • [16]

    She M, Laudon M, Yin W. Melatonin receptors in diabetes: a potential new therapeutical target? Eur J Pharmacol. 2015;744:220–3. Google Scholar

  • [17]

    Mulder H. Melatonin signalling and type 2 diabetes risk: too little, too much or just right? Diabetologia. 2017;60:826–9. PubMedCrossrefGoogle Scholar

  • [18]

    Peschke E, Bähr I, Mühlbauer E. Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon. Int J Mol Sci. 2013;14:6981–7015. CrossrefPubMedGoogle Scholar

  • [19]

    Peschke E, Bach AG, Mühlbauer E. Parallel signaling pathways of melatonin in the pancreatic β-cell. J Pineal Res. 2006;40:184–91. CrossrefPubMedGoogle Scholar

  • [20]

    La Fleur SE, Kalsbeek A, Wortel J, Van Der Vliet J, Buijs RM. Role for the pineal and melatonin in glucose homeostasis: pinealectomy increases night- time glucose concentrations. J Neuroendocrinol. 2001;13:1025–32. PubMedGoogle Scholar

  • [21]

    Singh M, Jadhav HR. Melatonin: functions and ligands. Drug Discov Today. 2014;19:1410–8. CrossrefPubMedGoogle Scholar

  • [22]

    Nagorny CL, Sathanoori R, Voss U, Mulder H, Wierup N. Distribution of melatonin receptors in murine pancreatic islets. J Pineal Res. 2011;50:412–7. PubMedCrossrefGoogle Scholar

  • [23]

    Picinato MC, Hirata AE, Cipolla-Neto J, Curi R, Carvalho CR, Anhê GF, et al. Activation of insulin and IGF-1 signaling pathways by melatonin through MT1 receptor in isolated rat pancreatic islets. J Pineal Res. 2008;44:88–94. PubMedGoogle Scholar

  • [24]

    Akmali M, Ahmadi R, Vessal M. Pre- and post-treatment of streptozocin administered rats with melatonin: effects on some hepatic enzymes of carbohydrate metabolism. Arch Iran Med. 2010;13:105–10. PubMedGoogle Scholar

  • [25]

    Fonken LK, Nelson RJ. The effects of light at night on circadian clocks and metabolism. Endocr Rev. 2014;35:648–70. PubMedCrossrefGoogle Scholar

  • [26]

    Greenhill C. Risk factors: melatonin signalling implicated in the risk of T2DM. Nat Rev Endocrinol. 2016;12:374. PubMedCrossrefGoogle Scholar

  • [27]

    Peschke E, Frese T, Chankiewitz E, Peschke D, Preiss U, Schneyer U, et al. Diabetic Goto Kakizaki rats as well as type 2 diabetic patients show a decreased diurnal serum melatonin level and an increased pancreatic melatonin-receptor status. J Pineal Res. 2006;40:135–43. CrossrefPubMedGoogle Scholar

  • [28]

    Cavalcanti-proenc C, Bouatia-naji N, Sparso T, Rocheleau G, Holmkvist J, Marchand M, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet. 2009;41:89–94. PubMedCrossrefGoogle Scholar

  • [29]

    Karamitri A, Jockers R. Melatonin in type 2 diabetes mellitus and obesity. Nat Rev Endocrinol [Internet]. 2019;15:105–25. CrossrefGoogle Scholar

  • [30]

    Jonsson A, Ladenvall C, Ahluwalia TS, Kravic J, Krus U, Taneera J, et al. Effects of common genetic variants associated with type 2 diabetes and glycemic traits on α- and β-cell function and insulin action in humans. Diabetes. 2013;62:2978–83. CrossrefPubMedGoogle Scholar

  • [31]

    Walford GA, Green T, Neale B, Isakova T, Rotter JI, Grant SF, et al. Common genetic variants differentially influence the transition from clinically defined states of fasting glucose metabolism. Diabetologia. 2012;55:331–9. PubMedCrossrefGoogle Scholar

  • [32]

    Tuomi T, Nagorny CL, Singh P, Bennet H, Yu Q, Alenkvist I, et al. Increased melatonin signaling is a risk factor for type 2 diabetes. Cell Metab. 2016;23:1067–77. CrossrefPubMedGoogle Scholar

  • [33]

    Gaulton KJ, Ferreira T, Lee Y, Raimondo A, Mägi R, Reschen ME, et al. Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. Nat Genet. 2015;47:1415–25. CrossrefPubMedGoogle Scholar

  • [34]

    Karamitri A, Renault N, Clement N, Guillaume JL, Jockers R. Minireview: toward the establishment of a link between melatonin and glucose homeostasis: association of melatonin MT2 receptor variants with type 2 diabetes. Mol Endocrinol. 2013;27:1217–33. CrossrefPubMedGoogle Scholar

  • [35]

    Yeǧin ZA, Mutluay R, Elbeg Ş, Karakuş R, Çakir N. The impact of melatonin on glucose homeostasis. Turkish J Endocrinol Metab. 2009;13:52–5. Google Scholar

  • [36]

    Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, Thorleifsson G, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet. 2009;41:77–81. PubMedCrossrefGoogle Scholar

  • [37]

    Peschke E, Stumpf I, Bazwinsky I, Litvak L, Dralle H, Mühlbauer E. Melatonin and type 2 diabetes – a possible link? J Pineal Res. 2007;42:350–8. CrossrefPubMedGoogle Scholar

  • [38]

    Mulder H, Nagorny CL, Lyssenko V, Groop L. Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene. Diabetologia. 2009;52:1240–9. PubMedCrossrefGoogle Scholar

  • [39]

    Agil A, Rosado I, Ruiz R, Figueroa A, Zen N, Fernández-Vázquez G. Melatonin improves glucose homeostasis in young Zucker diabetic fatty rats. J Pineal Res. 2012;52:203–10. PubMedCrossrefGoogle Scholar

  • [40]

    Hussain SA, Khadim HM, Khalaf BH, Ismail SH, Hussein KI, Sahib AS. Effects of melatonin and zinc on glycemic control in type 2 diabetic patients poorly controlled with metformin. Saudi Med J. 2006;27:1483–8. PubMedGoogle Scholar

  • [41]

    Peschke E, Hofmann K, Bähr I, Streck S, Albrecht E, Wedekind D, et al. The insulin-melatonin antagonism: studies in the LEW.1AR1-iddm rat (an animal model of human type 1 diabetes mellitus). Diabetologia. 2011;54:1831–40. PubMedCrossrefGoogle Scholar

  • [42]

    Peschke E, Wolgast S, Bazwinsky I, Pönicke K, Muhlbauer E. Increased melatonin synthesis in pineal glands of rats in streptozotocin induced type 1 diabetes. J Pineal Res. 2008;45:439–48. CrossrefPubMedGoogle Scholar

  • [43]

    Owino S, Contreras-Alcantara S, Baba K, Tosini G. Melatonin signaling controls the daily rhythm in blood glucose levels independent of peripheral clocks. PLoS One. 2016;11:1–16. Google Scholar

  • [44]

    Lima FB, Machado UF, Bartol I, Seraphim PM, Sumida DH, Moraes SM, et al. Pinealectomy causes glucose intolerance and decreases adipose cell responsiveness to insulin in rats. Am J Physiol Metab. 2017;275:E934–41. Google Scholar

  • [45]

    Galano A, Tan DX, Reiter RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res. 2011;51:1–16. CrossrefPubMedGoogle Scholar

  • [46]

    Kdziora-Kornatowska K, Szewczyk-Golec K, Kozakiewicz M, Pawluk H, Czuczejko J, Kornatowski T, et al. Melatonin improves oxidative stress parameters measured in the blood of elderly type 2 diabetic patients. J Pineal Res. 2009;46(3):333–7. CrossrefPubMedGoogle Scholar

  • [47]

    Mayo JC, Sainz RM, Antolín I, Herrera F, Martin V, Rodriguez C. Melatonin regulation of antioxidant enzyme gene expression. Cell Mol Life Sci. 2002;59:1706–13. CrossrefPubMedGoogle Scholar

  • [48]

    Hadjzadeh MA, Alikhani V, Hosseinian S, Zarei B, Keshavarzi Z. The effect of melatonin against gastric oxidative stress and dyslipidemia in streptozotocin-induced diabetic rats. Acta Endocrinol (Buchar). 2018;14:453–8. PubMedCrossrefGoogle Scholar

  • [49]

    Luhinich N, Gerush I. Effects of 7-day melatonin introduction on the hydrogen sulfide production and glutathione system in the liver of alloxan induced diabetic rats. Georg Med News. 2019;289:135–9. Google Scholar

  • [50]

    Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058–70. CrossrefPubMedGoogle Scholar

  • [51]

    Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–20. CrossrefPubMedGoogle Scholar

  • [52]

    Zephy D, Ahmad J. Type 2 diabetes mellitus: role of melatonin and oxidative stress. Diabetes Metab Syndr. 2015;9:127–31. CrossrefPubMedGoogle Scholar

  • [53]

    Wan XD, Li SQ, Xi SM, Wang JF, Guo YC, Wang XM. Long-term melatonin administration improves glucose homeostasis and insulin resistance state in high-fat diet fed rats. Cent Eur J Biol. 2013;8:958–67. Google Scholar

  • [54]

    Lo CC, Lin SH, Chang JS, Chien YW. Effects of melatonin on glucose homeostasis, antioxidant ability, and adipokine secretion in ICR mice with NA/STZ-induced hyperglycemia. Nutrients. 2017;9:1187–200. CrossrefGoogle Scholar

  • [55]

    Rybka J, Kędziora-kornatowska K, Kupczyk D, Muszalik M, Kornatowski M, Kędziora J. Antioxidant effect of immediate- versus sustained-release melatonin in type 2 diabetes mellitus and healthy controls. Drug Deliv. 2016;23:814. PubMedGoogle Scholar

  • [56]

    Bonnefond A, Froguel P. The case for too little melatonin signalling in increased diabetes risk. Diabetologia. 2017;60:823–5. PubMedCrossrefGoogle Scholar

  • [57]

    Amaral FG, Turati AO, Barone M, Scialfa JH, Do Carmo Buonfiglio D, Peres R, et al. Melatonin synthesis impairment as a new deleterious outcome of diabetes-derived hyperglycemia. J Pineal Res. 2014;57:67–79. CrossrefPubMedGoogle Scholar

  • [58]

    Sharma S, Singh H, Ahmad N, Mishra P, Tiwari A. The role of melatonin in diabetes: therapeutic implications. Arch Endocrinol Metab. 2015;59:391–9. CrossrefPubMedGoogle Scholar

  • [59]

    Sartori C, Dessen P, Mathieu C, Monney A, Bloch J, Nicod P, et al. Melatonin improves glucose homeostasis and endothelial vascular function in high-fat diet-fed insulin-resistant mice. Endocrinology. 2009;150:5311–7. CrossrefPubMedGoogle Scholar

  • [60]

    de Oliveira AC, Andreotti S, Farias Tda S, Torres-Leal FL, De Proença AR, Campaña AB, et al. Metabolic disorders and adipose tissue insulin responsiveness in neonatally STZ-induced diabetic rats are improved by long-term melatonin treatment. Endocrinology. 2012;153:2178–88. CrossrefPubMedGoogle Scholar

  • [61]

    de Oliveira AC, Andreotti S, Sertie RA, Campana AB, de Proença AR, Vasconcelos RP, et al. Combined treatment with melatonin and insulin improves glycemic control, white adipose tissue metabolism and reproductive axis of diabetic male rats. Life Sci. 2018;199:158–66. CrossrefPubMedGoogle Scholar

  • [62]

    Bundhun PK, Bhurtu A, Yuan J. Impact of type 2 diabetes mellitus on the long-term mortality in patients who were treated by coronary artery bypass surgery. Med (Baltimore). 2017;96:e7022. Google Scholar

  • [63]

    Rathmann W, Giani G. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:2568–9. CrossrefPubMedGoogle Scholar

  • [64]

    Raygan F, Ostadmohammadi V, Bahmani F, Reiter RJ, Asemi Z. Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: a randomized, double-blind, placebo-controlled trial. Clin Nutr. 2019;38:191–6. PubMedCrossrefGoogle Scholar

  • [65]

    Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord. 2010;11:31–9. PubMedCrossrefGoogle Scholar

  • [66]

    Zhou H, Yue Y, Wang J, Ma Q, Chen Y. Melatonin therapy for diabetic cardiomyopathy: a mechanism involving Syk-mitochondrial complex I-SERCA pathway. Cell Signal. 2018;47:88–100. CrossrefPubMedGoogle Scholar

  • [67]

    Amin AH, El-Missiry MA, Othman Al. Melatonin ameliorates metabolic risk factors, modulates apoptotic proteins, and protects the rat heart against diabetes induced apoptosis. Eur J Pharmacol. 2014;747(December):166–73. PubMedGoogle Scholar

  • [68]

    Ouyang C, You J, Xie Z. The interplay between autophagy and apoptosis in the diabetic heart. J Mol Cell Cardiol. 2014;71:71–80. PubMedCrossrefGoogle Scholar

  • [69]

    Xiong FY, Tang ST, Su H, Tang HQ, Jiang P, Zhou Q, et al. Melatonin ameliorates myocardial apoptosis by suppressing endoplasmic reticulum stress in rats with long – term diabetic cardiomyopathy. Mol Med Rep. 2018;17:374–81. Google Scholar

  • [70]

    Wang W, Wang W, Azadzoi KM, Dai P, Wang Q, Sun J, et al. Alu RNA accumulation in hyperglycemia augments oxidative stress and impairs eNOS and SOD2 expression in endothelial cells. Mol Cell Endocrinol. 2016;426:91–100. CrossrefPubMedGoogle Scholar

  • [71]

    Li C, Lv L, Li H, Yu D. Cardiac fibrosis and dysfunction in experimental diabetic cardiomyopathy are ameliorated by alpha-lipoic acid. Cardiovasc Diabetol. 2012;11:1–10. Google Scholar

  • [72]

    Salmanoglu DS, Gurpinar T, Vural K, Ekerbicer N, Darıverenli E, Var A. Melatonin and L-carnitin improves endothelial disfunction and oxidative stress in type 2 diabetic rats. Redox Biol. 2016;8:199–204. PubMedCrossrefGoogle Scholar

  • [73]

    Manchester LC, Coto-Montes A, Boga JA, Andersen LP, Zhou Z, Galano A, et al. Melatonin: an ancient molecule that makes oxygen metabolically tolerable. J Pineal Res. 2015;59:403–19. PubMedCrossrefGoogle Scholar

  • [74]

    Kandemir YB, Tosun V, Güntekin Ü. Melatonin protects against streptozotocin-induced diabetic cardiomyopathy through the mammalian target of rapamycin (mTOR) signaling pathway. Adv Clin Exp Med. 2019;28:1171–7. PubMedCrossrefGoogle Scholar

  • [75]

    Behram Kandemir Y, Guntekin Ü, Tosun V, Korucuk N, Bozdemir MN. Melatonin protects against streptozotocin-induced diabetic cardiomyopathy by the phosphorylation of vascular endothelial growth factor-A (VEGF-A). Cell Mol Biol (Noisy-le-grand). 2018;64:47–52. CrossrefPubMedGoogle Scholar

  • [76]

    Dal B, Francisco S, Parente EB, Carolina A, Campos N, Cury AN, et al. Hyperglycemia effect on coronary disease in patients with metabolic syndrome evaluated by intracoronary ultrasonography. PLoS One 2017;12:1–9. Google Scholar

  • [77]

    Michaelson J, Hariharan V, Huang H. Hyperglycemic and hyperlipidemic conditionsalter cardiac cell biomechanical properties. Biophys J. 2014;106:2322–9. CrossrefPubMedGoogle Scholar

  • [78]

    Kwong B, Tan H, Hong C, Natesan P. Anti-diabetic activity of the semi-purified fractions of Averrhoa bilimbi in high fat diet fed-streptozotocin-induced diabetic rats. Life Sci. 2005;76:2827–39. CrossrefPubMedGoogle Scholar

  • [79]

    Agil A, Navarro-Alarcon M, Ruiz R, Abuhamadah S, El-Mir MY, Vazquez GF. Beneficial effects of melatonin on obesity and lipid profile in young Zucker diabetic fatty rats. J Pineal Res. 2011;50:207–12. PubMedGoogle Scholar

  • [80]

    Tengattini S, Russel J, Tan D, Pilar M, Rodella LF. Cardiovascular diseases: protective effects of melatonin. J Pineal Res. 2008;44:16–25. PubMedGoogle Scholar

  • [81]

    Mehmeti I, Lenzen S, Lortz S. Modulation of Bcl-2-related protein expression in pancreatic beta cells by pro-inflammatory cytokines and its dependence on the antioxidative defense status. Mol Cell Endocrinol. 2011;332:88–96. PubMedCrossrefGoogle Scholar

  • [82]

    Baydas G, Reiter RJ, Akbulut M, Tuzcu M, Tamer S. Melatonin inhibits neural apoptosis induced by homocysteine in hippocampus of rats via inhibition of cytochrome c translocation and caspase-3 activation and by regulating pro- and anti-apoptotic protein levels. Neuroscience. 2005;135:879–86. CrossrefPubMedGoogle Scholar

  • [83]

    Yu L, Liang H, Lu Z, Zhao G, Zhai M, Yang Y, et al. Membrane receptor-dependent Notch1/Hes1 activation by melatonin protects against myocardial ischemia-reperfusion injury: in vivo and in vitro studies. J Pineal Res. 2015;59:420–33. PubMedCrossrefGoogle Scholar

  • [84]

    Yu L, Liang H, Dong X, Zhao G, Jin Z, Zhai M, et al. Reduced silent information regulator 1 signaling exacerbates myocardial ischemia-reperfusion injury in type 2 diabetic rats and the protective effect of melatonin. J Pineal Res. 2015;59:376–90. PubMedCrossrefGoogle Scholar

  • [85]

    Yu L, Di W, Dong X, Li Z, Zhang Y, Xue X, et al. Melatonin protects diabetic heart against ischemia-reperfusion injury, role of membrane receptor-dependent cGMP-PKG activation. BBA – Mol Basis Dis. 2018;1864:563–78. CrossrefGoogle Scholar

  • [86]

    Tang S, Su H, Zhang Q, Tang H, Wang C, Zhou Q, et al. Melatonin attenuates aortic endothelial permeability and arteriosclerosis in streptozotocin-induced diabetic rats: possible role of MLCK- and MLCP-dependent MLC phosphorylation. J Cardiovasc Pharmacol Ther. 2016;21:82–92. PubMedCrossrefGoogle Scholar

  • [87]

    Ding M, Feng N, Tang D, Feng J, Li Z, Jia M, et al. Melatonin prevents Drp1-mediated mitochondrial fission in diabetic hearts through SIRT1-PGC1α pathway. J Pineal Res. 2018;65:e12491. PubMedGoogle Scholar

  • [88]

    Mariappan N, Elks CM, Sriramula S, Guggilam A, Liu Z, Borkhsenious O, et al. NF-kappa B-induced oxidative stress contributes to mitochondrial and cardiac dysfunction in type II diabetes. Cardiovasc Res. 2010;85:473–83. CrossrefGoogle Scholar

  • [89]

    Verma SK, Garikipati VN, Kishore R. Mitochondrial dysfunction and its impact on diabetic heart. Biochim Biophys Acta Mol Basis Dis. 2017;1863:1098–105. PubMedCrossrefGoogle Scholar

  • [90]

    Wang S, Zhao Z, Feng X, Cheng Z, Xiong Z, Wang T, et al. Melatonin activates Parkin translocation and rescues the impaired mitophagy activity of diabetic cardiomyopathy through Mst1 inhibition. J Cell Mol Med. 2018;22:5132–44. CrossrefPubMedGoogle Scholar

  • [91]

    Hu J, Wang T, Man W, Yin T, Guo W, Gao E, et al. Melatonin protects against diabetic cardiomyopathy through Mst1/Sirt3 signaling. J Pineal Res. 2017;63:1–13. Google Scholar

  • [92]

    Rangasamy S, Mcguire PG, Das A. Diabetic retinopathy and inflammation: novel therapeutic targets. Middle East Afr J Ophthalmol. 2012;19:52–29. PubMedCrossrefGoogle Scholar

  • [93]

    Mitsuhashi J, Morikawa S, Shimizu K, Ezaki T, Yasuda Y. Intravitreal injection of erythropoietin protects against retinal vascular regression at the early stage of diabetic retinopathy in streptozotocin-induced diabetic rats. Exp Eye Res. 2013;106:64–73. PubMedCrossrefGoogle Scholar

  • [94]

    Masoud RE. Prevention of diabetic retinopathy by melatonin in rats with STZ induced diabetes mellitus. Int J Sci Res. 2017;6:843–7. Google Scholar

  • [95]

    Gundogan FC, Yolcu U, Akay F, Ilhan A, Ozge G, Uzun S. Diabetic macular edema. Pak J Med Sci. 2016;32:505–10. PubMedGoogle Scholar

  • [96]

    Crooke A, Basilio FH, Jesús C. The role and therapeutic potential of melatonin in age related ocular diseases. J Pineal Res. 2017;63:1–25. Google Scholar

  • [97]

    Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic. Diabetes Care. 2003;26:2653–64. PubMedGoogle Scholar

  • [98]

    Dehdashtian E, Mehrzadi S, Yousefi B, Hosseinzadeh A, Reiter RJ, Safa M, et al. Diabetic retinopathy pathogenesis and the ameliorating effects of melatonin; involvement of autophagy, inflammation and oxidative stress. Life Sci. 2018;193:20–33. PubMedCrossrefGoogle Scholar

  • [99]

    Santos JM, Tewari S, Kowluru RA. A compensatory mechanism protects retinal mitochondria from initial insult in diabetic retinopathy. Free Radic Biol Med. 2012;53:1729–37. PubMedCrossrefGoogle Scholar

  • [100]

    Djordjevic B, Cvetkovic T, Jevtovic T, Despotovic M, Zivanovic S, Basic J, et al. Oral supplementation with melatonin reduces oxidative damage and concentrations of inducible nitric oxide synthase, VEGF and matrix metalloproteinase 9 in the retina of rats with streptozotocin/nicotinamide induced pre-diabetes. Eur J Pharmacol. 2018;833:290–7. CrossrefPubMedGoogle Scholar

  • [101]

    Ozdemir G, Ergün Y, Bakariş S, Kılınç M, Durdu H, Ganiyusufoğlu E. Melatonin prevents retinal oxidative stress and vascular changes in diabetic rats. Eye (Lond). 2014;28:1020–7. PubMedCrossrefGoogle Scholar

  • [102]

    Salido EM, Zavalía N, Schreier L, De Laurentiis A, Rettori V, Chianelli M, et al. Retinal changes in an experimental model of early type 2 diabetes in rats characterized by non-fasting hyperglycemia. Exp Neurol. 2012;236:151–60. CrossrefGoogle Scholar

  • [103]

    Yang JH, Kwak HW, Kim TG, Han J, Moon SW, Yu SY. Retinal neurodegeneration in type II diabetic Otsuka Long-Evans Tokushima fatty rats. IOVS 2013;54:3844–51. Google Scholar

  • [104]

    Ellis EA, Guberski DL, Hutson B, Grant MB. Time course of NADH oxidase, inducible nitric oxide synthase and peroxynitrite in diabetic retinopathy in the BBZ/OR rat. Nitric Oxide Biol Chem. 2002;6:295–304. CrossrefGoogle Scholar

  • [105]

    Kumar A, Chen S, Kadiiska MB, Hong J, Zielonka J, Kalyanaraman B, et al. Inducible nitric oxide synthase is key to peroxynitrite-mediated, LPS-induced protein radical formation in murine microglial BV2 cells. Free Radic Biol Med. 2014;73:51–9. PubMedCrossrefGoogle Scholar

  • [106]

    Al-shabrawey M, Bartoli M, El-remessy AB, Ma G, Matragoon S, Lemtalsi T, et al. Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008;49:3231–8. PubMedCrossrefGoogle Scholar

  • [107]

    Kumawat M, Kharb S, Singh V, Singh N, Singh S, Nada M. Plasma malondialdehyde (MDA) and anti-oxidant status in diabetic retinopathy. J Indian Med Assoc. 2014;112:29–32. PubMedGoogle Scholar

  • [108]

    Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res. 2003;22:1–29. CrossrefPubMedGoogle Scholar

  • [109]

    Jiang T, Chang Q, Zhao Z, Yan S, Wang L, Cai J, et al. Melatonin-mediated cytoprotection against hyperglycemic injury in Muller cells. PLoS One 2012;7:1–8. Google Scholar

  • [110]

    Jiang T, Chang Q, Cai J, Fan J, Zhang X, Xu G. Protective effects of melatonin on retinal inflammation and oxidative stress in experimental diabetic retinopathy. Oxid Med Cell Longev. 2016;2016:3528274. PubMedGoogle Scholar

  • [111]

    Forman HJ, Zhang H, Rinna A. Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol Aspects Med. 2009;30:1–12. CrossrefPubMedGoogle Scholar

  • [112]

    Xie M, Hu A, Luo Y, Sun W, Hu X, Tang S. Interleukin-4 and melatonin ameliorate high glucose and interleukin-1β stimulated inflammatory reaction in human retinal endothelial cells and retinal pigment epithelial cells. Mol Vis. 2014;20:921–8. PubMedGoogle Scholar

  • [113]

    Salido EM, Bordone M, Laurentiis A, Chianelli M, Sarmiento MI, Dorfman D, et al. Therapeutic efficacy of melatonin in reducing retinal damage in an experimental model of early type 2 diabetes in rats. J Pineal Res. 2013;54:179–89. CrossrefGoogle Scholar

  • [114]

    Gul M, Emre S, Esrefoglu M, Vardı N. Protective effects of melatonin and aminoguanidine on the cornea in streptozotocin-induced diabetic rats. Cornea. 2008;27:795–801. CrossrefPubMedGoogle Scholar

  • [115]

    Singh R, Kishore L, Kaur N. Diabetic peripheral neuropathy: current perspective and future directions. Pharmacol Res. 2014;80:21–35. CrossrefPubMedGoogle Scholar

  • [116]

    Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev. 2012;28:8–14. CrossrefPubMedGoogle Scholar

  • [117]

    Tesfaye S, Vileikyte L, Rayman G, Sindrup SH, Perkins BA, Baconja M, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27:629–38. CrossrefPubMedGoogle Scholar

  • [118]

    Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285–93. CrossrefPubMedGoogle Scholar

  • [119]

    Callaghan BC, Cheng HT, Stables CL, Smith AL, Feldman EL. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012;11:521–34. PubMedCrossrefGoogle Scholar

  • [120]

    Feldman EL, Nave K, Jensen TS, Bennett DL. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. Neuron. 2017;93:1296–313. CrossrefPubMedGoogle Scholar

  • [121]

    Zenker J, Ziegler D, Chrast R. Novel pathogenic pathways in diabetic neuropathy. Trends Neurosci. 2013;36:439–49. CrossrefPubMedGoogle Scholar

  • [122]

    Kuhad A, Chopra K. Curcumin attenuates diabetic encephalopathy in rats: behavioral and biochemical evidences. Eur J Pharmacol. 2007;576:34–42. CrossrefPubMedGoogle Scholar

  • [123]

    Jangra A, Datusalia AK, Khandwe S, Sharma SS. Amelioration of diabetes-induced neurobehavioral and neurochemical changes by melatonin and nicotinamide: implication of oxidative stress–PARP pathway. Phamarcol Biochem Behav. 2013;114–115:43–51. Google Scholar

  • [124]

    Baydas G, Reiter RJ, Yasar A, Tuzcu M, Akdemir I, Nedzvetskii VS. Melatonin reduces glial reactivity in the hippocampus, cortex, and cerebellum of streptozotocin-induced diabetic rats. Free Radic Biol Med. 2003;35:797–804. CrossrefPubMedGoogle Scholar

  • [125]

    Metwally MM, Ebraheim LL, Galal AA. Potential therapeutic role of melatonin on STZ-induced diabetic central neuropathy: a biochemical, histopathological, immunohistochemical and ultrastructural study. Acta Histochem. 2018;120:828–36. CrossrefPubMedGoogle Scholar

  • [126]

    Leeboonngam T, Pramong R, Sae-ung K, Govitrapong P, Phansuwan-Pujito P. Neuroprotective effects of melatonin on amphetamine-induced dopaminergic fiber degeneration in the hippocampus of postnatal rats. J Pineal Res. 2018;64:1–19. Google Scholar

  • [127]

    Ali T, Rehman SU, Shah FA, Kim MO. Acute dose of melatonin via Nrf2 dependently prevents acute ethanol-induced neurotoxicity in the developing rodent brain. J Neuroinflammation. 2018;15:119–38. CrossrefPubMedGoogle Scholar

  • [128]

    Negi G, Kumar A, Joshi RP, Sharma SS. Biochemical and biophysical research communications oxidative stress and Nrf2 in the pathophysiology of diabetic neuropathy: old perspective with a new angle. Biochem Biophys Res Commun. 2011;408:1–5. CrossrefPubMedGoogle Scholar

  • [129]

    Negi G, Kumar A, Sharma SS. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-κB and Nrf2 cascades. J Pineal Res. 2011;50:124–31. PubMedGoogle Scholar

  • [130]

    Kireev RA, Cuesta S, Vara E, Tresguerres JA. Effect of growth hormone and melatonin on the brain: from molecular mechanisms to structural changes. Horm Mol Bio Clin Investig. 2011;7:337–50. Google Scholar

  • [131]

    Onphachanch X, Lee HJ, Lim JR, Jung YH, Kim JS, Chae CW, et al. Enhancement of high glucose-induced PINK1 expression by melatonin stimulates neuronal cell survival: involvement of MT2/Akt/NF-κB pathway. J Pineal Res. 2017;63:1–17. Google Scholar

  • [132]

    Tiong YL, Ng KY, Koh RY, Ponnudurai G, Chye SM. Melatonin prevents oxidative stress-induced mitochondrial dysfunction and apoptosis in high glucose-treated schwann cells via upregulation of Bcl2, NF-κB, mTOR, Wnt signalling pathways. Antioxidants (Basel). 2019;8: 1– 15. Google Scholar

  • [133]

    Song J, Kim OY. Melatonin modulates neuronal cell death induced by endoplasmic reticulum stress under insulin resistance condition. Nutrients. 2017;9:593–608. CrossrefGoogle Scholar

  • [134]

    Zangiabadi N, Sheibani V, Asadi-Shekaari M, Shabani M, Jafari M, Asadi AR, et al. Effects of melatonin in prevention of neuropathy in STZ-induced diabetic rats. Am J Pharmacol Toxicol. 2011;6:59–67. CrossrefGoogle Scholar

  • [135]

    Gokce S, Dincer M, Yaraneri H. Electrophysiological and theoretical analysis of melatonin in peripheral nerve crush injury. J Neurosci Methods. 2010;191:277–82. CrossrefPubMedGoogle Scholar

  • [136]

    Seyit DA, Degirmenci E, Oguzhanoglu A. Evaluation of electrophysiological effects of melatonin and alpha lipoic acid in rats with streptozotocine induced diabetic neuropathy. Exp Clin Endocrinol Diabetes. 2016;124:300–6. CrossrefPubMedGoogle Scholar

  • [137]

    Chang HM, Liu CH, Hsu WM, Chen LY, Wang HP, Wu TH, et al. Proliferative effects of melatonin on Schwann cells : implication for nerve regeneration following peripheral nerve injury. J Pineal Res. 2014;56:322–32. PubMedCrossrefGoogle Scholar

About the article

Received: 2019-06-27

Accepted: 2019-10-01

Published Online: 2019-11-06

Author statement

Author contributions: JXM and JHO wrote the manuscript, and KYN and RYK critically reviewed the manuscript. SMC formulated the entire concept and reviewed the manuscript.

Research funding: None declared.

Conflict of interest: None declared.

Informed consent: Not applicable.

Ethical approval: Not applicable.

Citation Information: Hormone Molecular Biology and Clinical Investigation, Volume 40, Issue 1, 20190036, ISSN (Online) 1868-1891, DOI: https://doi.org/10.1515/hmbci-2019-0036.

Export Citation

© 2019 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in